Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial; REC602, recombinant HPV bivalent vaccines targeting HPV type 6/11, which is in phase I clinical trials; REC604a, a novel adjuvanted recombinant HPV quadrivalent vaccine; and REC604c, a recombinant HPV 9-valent vaccine. It also develops REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC625, a bivalent recombinant respiratory syncytial virus vaccine and REC627, a recombinant metapneumovirus vaccine for the treatment of respiratory diseases caused by respiratory syncytial virus; REC609, a recombinant human cytomegalovirus vaccine for the treatment of human cytomegalovirus disease; and ReCOV, a recombinant bicomponent COVID-19 vaccine candidate that completed phase III clinical trial. In addition, the company develops REC629, a recombinant Hepatitis B virus vaccine and REC630, a therapeutic recombinant Hepatitis B virus vaccine for the treatment of disease caused by hepatitis B virus infection; REC608, a recombinant herpes simplex virus vaccine; and REC617, a recombinant influenza vaccine. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People's Republic of China.
